Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor α in patients with advanced non-small cell lung cancer : a phase I trial

Sixteen patients with metastatic non-small cell lung cancer were treated with a combination of simultaneous low-dose interleukin 2 (IL-2) and tumor necrosis factor alpha. The purpose of this phase I dose escalation trial was to assess the clinical toxicities, immunomodulatory effects, and antitumor...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Ill.), 1991-07, Vol.51 (14), p.3669-3676
Hauptverfasser:	YANG, S. C, GRIMM, E. A, PARKINSON, D. R, CARINHAS, J, FRY, K. D, MENDIGUREN-RODRIGUEZ, A, LICCIARDELLO, J, OWEN-SCHAUB, L. B, HONG, W. K, ROTH, J. A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Antigens, Surface - analysis Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Carcinoma, Non-Small-Cell Lung - immunology Carcinoma, Non-Small-Cell Lung - therapy Drug Evaluation Humans Immunotherapy Interleukin-2 - administration & dosage Interleukin-2 - adverse effects Interleukin-2 - analysis Killer Cells, Lymphokine-Activated - immunology Killer Cells, Natural - immunology Lung Neoplasms - immunology Lung Neoplasms - therapy Medical sciences Middle Aged Pharmacology. Drug treatments T-Lymphocytes - immunology Tumor Necrosis Factor-alpha - administration & dosage Tumor Necrosis Factor-alpha - adverse effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!